The Setup

ClearPoint Neuro filed its 10-K on March 17, 2026. The stock fell 13% that day.

The market saw: GAAP net loss widened to $25.5M from $18.9M. Operating cash outflow jumped to $23.9M from $9.0M prior year. EPS missed estimates by 22%. Guidance midpoint trimmed from $57M (Q3 call) to $54M.

What the market priced in: a deteriorating business with growing losses and acceleration toward a cash crisis.

What the filing actually shows: Q4 2025 was the best quarter in the company's history. Revenue beat estimates. The biologics segment — the core thesis — re-accelerated exactly when management said it would. Cash burn was inflated by $10.6M of one-time IRRAS acquisition liability paydowns that the company explicitly disclosed will not recur. Normalized burn is $13–15M/year against $45.9M cash and an additional $25M drawable from Oberland at the company's option, with no financial covenants, through 2031. All four named C-suite officers — CEO, CFO, COO, and one additional officer — bought $2.78M of stock in the open market on March 6 and March 12. One week before this filing.

The gap between what the market sees and what the filing says is where this thesis lives.

What the Filing Shows

FY2025 results:

The gross margin line matters: 11th consecutive year of revenue growth, flat gross margins through an acquisition integration year. That's operational discipline.

Q4 2025 was the signal quarter:

• Total revenue: $10.4M (+34% YoY, +19% organic ex-IRRAflow)
• Biologics/drug delivery: $5.2M (+23% YoY)
• Gross margin: 62%

The biologics re-acceleration is not a small point. CLPT's drug delivery segment posted flat services revenue through Q1–Q3 2025 while the company moved to its new ClearPoint Advanced Labs (CAL) facility in San Diego. Management guided Q4 recovery. Q4 delivered +23%. The concern was real. The resolution was also real.

The G&A miss explained: G&A jumped 38% to $16.5M. The drivers: $1.4M IRRAS severance, $1.0M professional fees, $0.9M headcount additions, $0.2M bad debt. Roughly $3.3M was IRRAS one-time integration cost. Strip it out and G&A growth was 11%. The market saw -22% EPS and didn't ask why.

Cash picture: The auditor (Cherry Bekaert LLP, same firm since 2008) issued a clean opinion. The going concern language that appears in the risk factors is conditional boilerplate — "if we are unable to raise additional capital" — not an auditor-triggered accounting event. Management stated cash is "sufficient to support operations for at least the next twelve months." The operative liquidity number is $70.9M accessible capital ($45.9M cash + $25M additional Oberland tranche at company's option), against normalized burn of $13–15M/year. Runway is 4–5 years at current burn rate.

2026 guidance: $52–56M (+41–51%). CEO: "We expect all four of these product lines to grow double digits in 2026."

The Platform Thesis

ClearPoint Neuro is not a device company. It is an infrastructure company for CNS gene therapy delivery.

The core product is a neurosurgical navigation system that lets surgeons target specific brain structures — the putamen, striatum, deep nuclei — under real-time MRI guidance. The SmartFlow cannula delivers the therapy at the target site with sub-millimeter precision. Every CNS gene therapy that requires intracranial delivery needs exactly this capability.

The AADC leg of the thesis is no longer speculative. PTC Therapeutics received FDA approval for Kebilidi (eladocagene exuparvovec) in November 2024 — the first brain-administered gene therapy ever approved in the United States. It is delivered via bilateral putaminal injection under MRI guidance. ClearPoint's SmartFlow cannula received FDA De Novo authorization as the delivery device for this indication. Commercial procedures are being performed now. PTCT ends 2025 with $1.95B in cash and 12-year exclusivity on Kebilidi. PTCT accounts for 15% of CLPT's biologics revenue — roughly $2.85M/year currently. The AADC patient population in the US is approximately 500–1,500 diagnosed patients; as diagnostic awareness improves, that base grows.

The regulatory moat is real and specific. Any future AADC therapy needs either its own delivery device clearance — a years-long De Novo process — or it uses the one device already cleared. That is ClearPoint.

Beyond AADC: 60+ pharma and biotech partners are working with the ClearPoint platform. Nine of them are in FDA expedited review programs (Fast Track, Breakthrough Designation, or RMAT) covering AADC, Hunter syndrome, Huntington's disease, drug-resistant epilepsy, Parkinson's disease, frontotemporal dementia, and Friedreich's ataxia. Management estimates $300M/year additional revenue at 1% annual treatment penetration of those indications alone.

That $300M figure requires believing in multiple approvals. The right way to think about it is as option value on a staged wave, not as a revenue forecast.

The CAL facility is the key investment that underpins 2026 guidance. The new 30,171 sq ft life science building in San Diego (leased June 2025, three-phase buildout, final phase available July 2026) enables studies 4–5x larger than the old facility and GLP-standard studies required for FDA submissions. CLPT is now bidding on $5–10M single studies versus a prior maximum of approximately $2M. This is the mechanism behind the biologics segment acceleration. It is already running.

IRRAflow is the second leg added by the IRRAS acquisition (closed November 2025). IRRAflow is an automated drainage and ICP monitoring device for neurocritical care — a $500M+ addressable market per management, entirely separate from gene therapy. It contributed $1.2M in a partial Q4. The acquisition cost $5M cash plus shares; the gross margin on IRRAflow runs in the mid-50s%, below CLPT's 61% average but on a clear scale-up path. This adds a second recurring disposable revenue stream that diversifies away from the binary nature of gene therapy partner outcomes.

Cross-Ticker Corroboration

The PTCT check adds material confidence. PTCT's 10-K (filed February 2026) confirms Kebilidi commercial launch in the US in H2 2025, explicitly cites "increase in net product sales of Sephience and Upstaza/Kebilidi" as a driver of YoY revenue improvement, and shows $1.95B in cash with Kebilidi carrying 12-year BPCIA exclusivity. PTCT is not a struggling company running a speculative trial. It is executing a commercial launch of the first brain gene therapy, using ClearPoint's platform, with a decade of protected pricing runway. This is the AADC wave happening.

The Huntington's check reveals a meaningful setback. FDA's March 2026 Type A meeting with uniQure concluded they "cannot agree" that Phase 1/2 data using an external control is sufficient for a BLA. FDA mandated a full sham-surgery Phase 3 RCT. uniQure's AMT-130 — almost certainly CLPT's Huntington's expedited-review partner — is now a 5+ year story rather than a 2026–2027 catalyst. The biology is intact (75% progression slowing, p=0.003); the methodology is the problem. And notably, the Phase 3 design requires intracranial delivery on the active arm and sham surgery on the control arm — meaning ClearPoint still benefits when the trial runs. But near-term, the HD leg is deferred.

Passage Bio's FTD program (upliFT-D, Cohort 3 enrolling) represents a second nuance. PBFT02 is administered via intra-cisterna magna (ICM) injection — a suboccipital approach — rather than parenchymal injection through ClearPoint's stereotactic system. CLPT may have a partial role but is not the primary enabler. Additionally, PASG's cash position covers only through Q1 2027; going concern risk is real for this specific partner.

The net of cross-ticker work: the AADC wave has already broken the first regulatory barrier, PTCT is well-capitalized and executing, but the pipeline-to-revenue conversion timeline is 5–8 years for the full thesis rather than 2–3. The right tail of the thesis is compressed by one FDA ruling. The core is confirmed.

Bear Case

Three legitimate risks:

Path to profitability is distant. At $52–56M 2026 revenue with 61% gross margins, gross profit is $32–34M. Current opex run rate is approximately $47M and will grow as the commercial organization expands. Operating losses remain $15–20M through 2026 even on guidance. Profitable timeline: 2028–2029 at best, if guidance is hit and opex growth is disciplined. At $9.70, the stock trades at 5.3x 2026E EV/Revenue. That is not cheap for a loss-making medtech — unless you believe the 2027–2028 revenue inflection is real.

Debt structure has teeth. $50.9M to Oberland Capital at an effective 11.3% rate, secured by all company assets including IP. No financial covenants is a genuine positive — covenant-triggered acceleration is off the table. But Oberland's revenue participation kicker starts January 2027 at 0.525% of net revenue per quarter, and the debt matures in 2031. Prepayment premiums run 117.5–135% in years 1–3. The capital structure rewards execution and punishes delays.

Gene therapy partner risk is structural. CLPT's drug delivery revenue depends entirely on the clinical success and commercial execution of its partners' therapies. CLPT has no control over these outcomes. Of the 9 expedited-review programs, the HD leg is explicitly delayed and the FTD leg is underfunded. Each additional partner setback narrows the pipeline optionality and delays the revenue inflection that justifies current losses.

Valuation

Enterprise value at $9.70 is approximately $285M ($280M market cap + $50.9M debt − $45.9M cash).

EV/2026E revenue: 5.3x.

For context: a medtech company growing revenue at 40%+ with 61% gross margins and a regulatory moat in an FDA-validated commercial market typically trades at 8–10x forward revenue. The current multiple reflects market uncertainty about execution, an opaque GAAP loss presentation, and thin analyst coverage (two firms). The valuation implies roughly a 40–45% probability that management hits its 2026 guidance — against a 62% estimate from this analysis, based on Q4 re-acceleration data, CAL facility contribution, and IRRAflow first full year.

The mispricing is not in the terminal value. It is in the near-term execution probability. The market is backward-extrapolating from the GAAP loss without adjusting for one-time acquisition costs, without reading the Q4 trajectory, and without calculating the actual liquidity position.

Scenario distribution (12-month):

The setup is not a fat-tail lottery. The win/loss ratio is close to 1:1. The edge is in a 20-point probability differential on a near-term binary — whether Q1 2026 biologics confirms the Q4 re-acceleration or not.

Conclusion

The market sold a revenue beat because the EPS line was red. The EPS miss was integration costs from an acquisition closed six weeks before year-end. The underlying business in Q4 was the best quarter in the company's history.

The AADC thesis is no longer speculative. It is live, FDA-validated, and generating revenue now. Cross-ticker work confirms the delivery partner (PTCT) is well-capitalized and commercially executing. The regulatory moat — ClearPoint's SmartFlow as the only FDA De Novo authorized device for AADC delivery — means this revenue is sticky and defensible.

The bearable bear case is a slow wave: gene therapy approvals slip from 2027–2029 to 2029–2032, CLPT needs additional capital before reaching profitability, dilution compresses per-share value. That is a real 30% scenario.

The entry at $9.70 is inside the C-suite's cost basis. RSI is 29. The options market is not scared (P/C 0.30). Eleven percent of the float is short with 5.4 days to cover.

The binary is the Q1 2026 print, expected mid-May. If biologics growth comes in above 15% year-over-year and IRRAflow shows at least $1.5M in its first full quarter, the re-acceleration is confirmed and the position should be sized up. If biologics comes in below 10%, the re-acceleration was one quarter of noise and the thesis breaks.

The risk/reward supports a starter position at current levels, with full sizing contingent on Q1 2026 confirmation.

Evidence